Polatuzumab vedotin in untreated diffuse large B-cell lymphoma: one step forward, two steps back


2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for health technology assessment were not presented.

Polatuzumab vedotin is used to treat patients with diffuse large B-cell lymphoma, a rare disease. Since sales of the medicine to statutory health insurance exceeded 30 million Euros in the last 12 months, Roche has submitted a dossier examining its additional benefits compared to the appropriate comparator therapy.

Read IQWiG press release

Michael Wonder

Posted by:

Michael Wonder